undamentalytics Newsletter
Sign in

PRO DEX Inc (PDEX) stock

Add to watchlist

Add holding +

NASDAQ: PDEX Nasdaq Health Care Equipment Next results ~January 28, 2027

B Fundamentals grade

PRO DEX Inc is a US-listed company in the health care equipment industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($14.26) was left out of our combined valuation (it is more than 3x away from the median of our other models), so it can't be the basis of a rating.

Price vs value

Under review: our cash-flow value ($14.26) was left out of our combined valuation (it is more than 3x away from the median of our other models), so it can't be the basis of a rating. We'll show the comparison once resolved.

PRO DEX Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 20 sales by directors and officers, last 12 monthsInsider trades
  • Funds39 adding, 26 cuttingOf 8 active managers that changed their stake, 4 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter PRO DEX files

10-Q filed October 29: PRO DEX

Revenue for the twelve months to September 2026 was $80m, up 13.3% on a year earlier, slower than the 16.4% growth a quarter earlier. Free-cash-flow margin rose to 13.4% from -3.1% a year earlier.

Our model value for PRO DEX is under review, so past values are not shown until it is resolved.

Source: 10-Q filed October 29, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (2)

10-K filed September 3: PRO DEX

Pro-Dex's revenue for the twelve months to June 2026 reached $80m, a 13.3% rise on the prior year. That pace has eased from the 16.4% growth recorded a quarter earlier, suggesting momentum is cooling slightly. On profitability, the picture is more encouraging: free-cash-flow margin climbed to 13.4%, a marked turnaround from -3.1% a year before. Our model value has moved sharply in the other direction, falling from $53.55 to $14.84 a share. That leaves it far below the current share price of $63.09, a gap that is hard to ignore. Revenue growth may be softening and cash generation improving, but the valuation signal points to a stock trading well ahead of what the underlying numbers would justify.

10-K on SEC EDGAR

Where PRO DEX stands after its latest 10-K

Revenue for the twelve months to June 2026 was $78m, up 16.4% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin rose to 8.7% from -4.4% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 6 of our 7 financial-health checks.

10-K on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 28, 2027 (estimated)

PRO DEX Inc's trailing-twelve-month revenue grew 13.3% year on year, with a free-cash-flow margin of 13.4%. Where it stands out: stock pay as % of revenue of 0.8% ranks 4 of 123 health care equipment companies we cover. Where it lags: gross margin of 32.5% ranks 106 of 123 health care equipment companies we cover.

Our discounted-cash-flow model values the business at ~$14 per share in the base case (~$11–$19 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 37% in the quarter to 2026-09-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 1.8% in a year, so each share owns more of the business.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 55% and a beta of 1.2 against the S&P 500.
  • Growth easing. The growth rate is 3.1 points lower than a quarter earlier.
  • Below peers: gross margin. Gross margin of 32.5% ranks 106 of 123 health care equipment companies we cover (median 61.9%).
  • Below peers: days sales outstanding. Days sales outstanding of 80 days ranks 95 of 118 health care equipment companies we cover (median 57 days).
  • Heavily shorted. 30.9% of the shares available to trade are sold short (4.0 days of average volume to cover).

Latest results: FY2027 Q1

Filed October 29, 2026
Earnings per share
$0.92 against an average estimate of $0.67: beat by 37.3%
Revenue
$21m, up 11.0% on a year earlier
Share reaction
-8.0% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Next report
October 29, 2026; average EPS estimate $0.72

PRO DEX's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.9%
  • 1 week-5.0%
  • 1 month-10.0%
  • This year+49.8%
  • 1 year+59.1%
  • 5 years+129.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$79.6M
Operating margin
16.8%
Net margin
15.1%
EPS (TTM, diluted)
$3.63

Growth

Revenue growth
+13.3%
Change in growth rate
−3.1 pts
Share count change
−1.8%

Cash

Free cash flow (TTM)
$10.7M
FCF margin
13.4%
Stock pay % of revenue
0.8%

Earnings

Last results
October 29, 2026
Next results (est.)
January 28, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results
  3. Agreement
  4. Insider trade
  5. Results
  6. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

PRO DEX Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($14.26) was left out of our combined valuation (it is more than 3x away from the median of our other models), so it can't be the basis of a rating.

Our value per share comes from a discounted-cash-flow model of PRO DEX Inc's free cash flow after stock-based pay ( $1.4M, FY2027 Q1 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value PRO DEX Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.78 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$14 ~$11–$19 Left out: far from the other models (more than 3x away from their median)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$70 ~$74–$130 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$82 ~$56–$120 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$55 ~$46–$67 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare PRO DEX Inc with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026Now
Share price$5.56$6.15$6.65$12.98$17.82$30.56$15.95$19.10$19.64$43.64$58.55$57.65
Market value$23m$25m$29m$56m$73m$120m$60m$69m$70m$147m$194m$191m
+ Net debt (− = net cash)−$2m−$4m−$5m−$3m−$2m$10m$16m$14m$14m$21m$14m$5m
Enterprise value$21m$21m$24m$53m$71m$131m$76m$83m$84m$168m$208m$196m
Multiples
Price / sales 1.2x1.1x1.3x2.1x2.1x3.2x1.4x1.5x1.3x2.2x2.5x2.4x
Price / earnings 28.2x4.9x17.8x13.5x11.9x19.5x13.1x9.8x33.0x16.3x14.2x15.9x
Price / free cash flow 149.7x9.5x13.3x28.8x16.4x—————28.7x17.9x
EV / EBITDA 14.8x6.4x8.1x9.7x9.3x25.1x13.0x12.6x10.1x14.1x14.4x13.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

70 /100

Strong moat

How hard PRO DEX's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Net income has been a median 14.1% of total assets over 10 years.

  • Pricing power 10 / 20

    Gross margin has been a median 33.4%, moving by 3.6 percentage points (standard deviation) across 10 years.

  • Durability 14 / 20

    Operating margin has been a median 14.9%; its worst year was 10.9%.

  • Cash conversion 6 / 20

    Free cash flow was positive in 5 of 10 years, at a median 1.6% of revenue.

  • Discipline 20 / 20

    The diluted share count fell 18.1% over five years; stock-based pay has been a median 0.8% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $3.09 −25% $83m +7%
Next $3.36 +9% $87m +5%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +11.2% on 90 days ago. In the last 30 days, 1 analyst raised PRO DEX Inc's forecast and 0 cut it.

Consensus EPS forecast PRO DEX Inc, last 90 days
$2.70 $2.80 $2.90 $3.00 $3.10 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.78 Current fiscal year, 60 days ago: $2.78 Current fiscal year, 30 days ago: $2.78 Current fiscal year, 7 days ago: $2.78 Current fiscal year, Now: $3.09 $3.09

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal year
90 days ago $2.78
60 days ago $2.78
30 days ago $2.78
7 days ago $2.78
Now $3.09

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.67 $0.92 +37.3%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows PRO DEX Inc's revenue by +11.2% next year and +14.8% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+5.2%, weight 45%) and the company's own record (+16.3%, weight 55%) . How the weights are set.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611

Counts of recommendations published by analysts covering PRO DEX Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
30.9%
of tradable shares
Days to cover
3.98
at average volume
Short interest, 1 month
+12%
to October 15, 2026
Held by institutions
32%
of shares
Held by insiders
36.0%
of shares
Employees
201
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +59.1%

$36.24 on October 31, 2025 to $57.65

ThenNowEffect
Revenue (last 12 months) $67m $78m +16.4%
Net margin 13.5% 17.6% +30.7%
P/E multiple 13.6x 14.0x +3.2%
Share count 3m 3m +1.3%

Biggest factor: net margin.

Last 3 years +220.3%

$18.00 on November 3, 2023 to $57.65

ThenNowEffect
Revenue (last 12 months) $46m $78m +68.3%
Net margin 15.3% 17.6% +14.8%
P/E multiple 9.4x 14.0x +49.7%
Share count 4m 3m +10.8%

Biggest factor: revenue.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PDEX−25%−32%+10%+167%−18%+50%
Industry peers (median)−7%−37%−9%−20%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PDEX50%42%50%75%58%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PDEX−43%−49%−24%−27%−65%−22%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 69% from December 18, 2020 to May 9, 2022. Getting back needed a 224% gain, reached on November 6, 2024, 912 days after the low.

Price behaviour

52-week range
$28.91 – $73.41
From 52-week high
−21.5%
vs 50-day average
−10.8%
vs 200-day average
+1.8%
Volatility (1 year)
55%
Beta vs S&P 500
1.18

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±12.1%
After a week
5 up, 6 down
typical move ±15.3%
After a month
7 up, 4 down
typical move ±25.8%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 −8.0% −2.1% — —
September 3, 2026 +17.3% +0.7% +0.4% +4.5%
April 30, 2026 −3.0% +1.3% +15.2% +34.3%
January 29, 2026 −0.5% −0.5% −2.5% +17.0%
October 30, 2025 +18.0% −0.8% +6.1% +22.0%
September 4, 2025 −17.8% +0.5% −24.3% −26.8%
May 1, 2025 −30.2% +2.2% −34.0% −40.3%
January 30, 2025 −12.2% 0.0% −20.6% −16.6%
October 31, 2024 +21.1% −1.5% +34.8% +60.7%
September 5, 2024 +5.3% −1.9% +18.1% +40.5%
May 2, 2024 −1.9% +2.2% −0.9% +4.9%
February 8, 2024 −10.4% +0.6% −11.6% −16.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

PRO DEX Inc in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) PRO DEX Inc
$40M $50M $60M $70M $80M FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue (TTM), FY24 Q2: $48.2M Revenue (TTM), FY24 Q3: $49.5M Revenue (TTM), FY24 Q4: $53.8M Revenue (TTM), FY25 Q1: $56.8M Revenue (TTM), FY25 Q2: $61M Revenue (TTM), FY25 Q3: $64.1M Revenue (TTM), FY25 Q4: $66.6M Revenue (TTM), FY26 Q1: $70.2M Revenue (TTM), FY26 Q2: $72.1M Revenue (TTM), FY26 Q3: $74.6M Revenue (TTM), FY26 Q4: $77.5M Revenue (TTM), FY27 Q1: $79.6M $79.6M

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $48.2M
FY24 Q3 $49.5M
FY24 Q4 $53.8M
FY25 Q1 $56.8M
FY25 Q2 $61M
FY25 Q3 $64.1M
FY25 Q4 $66.6M
FY26 Q1 $70.2M
FY26 Q2 $72.1M
FY26 Q3 $74.6M
FY26 Q4 $77.5M
FY27 Q1 $79.6M
Revenue growth, TTM YoY PRO DEX Inc
0% 10% 20% 30% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue growth, TTM YoY, FY24 Q2: 9.0% Revenue growth, TTM YoY, FY24 Q3: 2.9% Revenue growth, TTM YoY, FY24 Q4: 16.8% Revenue growth, TTM YoY, FY25 Q1: 21.0% Revenue growth, TTM YoY, FY25 Q2: 26.4% Revenue growth, TTM YoY, FY25 Q3: 29.7% Revenue growth, TTM YoY, FY25 Q4: 23.7% Revenue growth, TTM YoY, FY26 Q1: 23.7% Revenue growth, TTM YoY, FY26 Q2: 18.2% Revenue growth, TTM YoY, FY26 Q3: 16.4% Revenue growth, TTM YoY, FY26 Q4: 16.4% Revenue growth, TTM YoY, FY27 Q1: 13.3% 13.3%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 9.0%
FY24 Q3 2.9%
FY24 Q4 16.8%
FY25 Q1 21.0%
FY25 Q2 26.4%
FY25 Q3 29.7%
FY25 Q4 23.7%
FY26 Q1 23.7%
FY26 Q2 18.2%
FY26 Q3 16.4%
FY26 Q4 16.4%
FY27 Q1 13.3%
Operating margin (TTM) PRO DEX Inc
12% 14% 16% 18% 20% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Operating margin (TTM), FY24 Q2: 13.0% Operating margin (TTM), FY24 Q3: 13.0% Operating margin (TTM), FY24 Q4: 13.3% Operating margin (TTM), FY25 Q1: 14.7% Operating margin (TTM), FY25 Q2: 16.8% Operating margin (TTM), FY25 Q3: 18.2% Operating margin (TTM), FY25 Q4: 16.1% Operating margin (TTM), FY26 Q1: 15.4% Operating margin (TTM), FY26 Q2: 15.7% Operating margin (TTM), FY26 Q3: 14.5% Operating margin (TTM), FY26 Q4: 16.8% Operating margin (TTM), FY27 Q1: 16.8% 16.8%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 13.0%
FY24 Q3 13.0%
FY24 Q4 13.3%
FY25 Q1 14.7%
FY25 Q2 16.8%
FY25 Q3 18.2%
FY25 Q4 16.1%
FY26 Q1 15.4%
FY26 Q2 15.7%
FY26 Q3 14.5%
FY26 Q4 16.8%
FY27 Q1 16.8%
FCF margin (TTM) PRO DEX Inc
-10% 0% 10% 20% FY22 Q2 FY23 Q1 FY25 Q4 FY27 Q1 FCF margin (TTM), FY22 Q2: -3.6% FCF margin (TTM), FY22 Q3: 7.7% FCF margin (TTM), FY22 Q4: -5.9% FCF margin (TTM), FY23 Q1: -3.8% FCF margin (TTM), FY23 Q2: -8.6% FCF margin (TTM), FY23 Q3: -3.4% FCF margin (TTM), FY25 Q4: -4.4% FCF margin (TTM), FY26 Q1: -3.1% FCF margin (TTM), FY26 Q2: 8.4% FCF margin (TTM), FY26 Q3: 9.3% FCF margin (TTM), FY26 Q4: 8.7% FCF margin (TTM), FY27 Q1: 13.4% 13.4%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY22 Q2 -3.6%
FY22 Q3 7.7%
FY22 Q4 -5.9%
FY23 Q1 -3.8%
FY23 Q2 -8.6%
FY23 Q3 -3.4%
FY25 Q4 -4.4%
FY26 Q1 -3.1%
FY26 Q2 8.4%
FY26 Q3 9.3%
FY26 Q4 8.7%
FY27 Q1 13.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2026, from the 10-K

Each dollar PRO DEX took in during FY2026, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $77.5M
  2. Other income $5M · 6.5%
  3. Cost of revenue $53.2M · 68.6%
  4. Gross profit $24.3M · 31.4%
  5. Research and development $3.3M · 4.3%
  6. Selling, general and admin $8M · 10.3%
  7. Operating income $13M · 16.8%
  8. Income tax $4.4M · 5.6%
  9. Net income $13.7M · 17.6%

Shares of revenue. Source: PRO DEX's 10-K for FY2026, as filed with the SEC. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Jun 2011 2012 Jun 2012 2013 Jun 2013 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 2026 Jun 2026 LTM Sept 2026
Income
Revenue 24 17 12 11 13 20 22 22 27 35 38 42 46 54 67 78 80
Gross profit 10 5 4 3 4 5 7 8 10 13 14 13 13 15 20 24 26
EBITDA 4 −1 −1 −0 −0 1 3 3 5 8 5 6 7 8 12 14 15
Operating income 3 −1 −2 −1 −1 1 3 2 5 7 5 5 6 7 11 13 13
Net income 3 −1 −2 −0 −0 1 5 2 4 6 6 5 7 2 9 14 12
Diluted EPS $0.80 −$0.27 −$0.54 −$0.14 −$0.09 $0.20 $1.25 $0.37 $0.97 $1.50 $1.57 $1.21 $1.95 $0.60 $2.67 $4.12 $3.63
Growth (year on year)
Revenue — −28.3% −29.0% −11.7% +23.8% +50.6% +8.9% +2.4% +21.0% +28.2% +9.2% +10.5% +9.6% +16.8% +23.7% +16.5% +13.3%
EBITDA — −117.2% — — — — +131.7% −10.4% +84.3% +40.5% −31.8% +12.2% +13.2% +25.9% +43.1% +20.6% +26.7%
Operating income — −139.2% — — — — +239.2% −12.6% +108.9% +41.4% −36.0% +13.2% +12.5% +24.5% +49.0% +21.5% +24.2%
Net income — −133.2% — — — — +518.5% −68.1% +155.9% +47.3% +0.9% −25.9% +54.7% −69.9% +322.1% +52.2% +7.5%
Diluted EPS — −133.8% — — — — +525.0% −70.4% +162.2% +54.6% +4.7% −22.9% +61.2% −69.2% +345.0% +54.3% +9.5%
Margins
Gross margin 42.1% 31.4% 30.3% 27.4% 27.7% 24.4% 32.7% 35.4% 36.0% 37.7% 35.7% 31.2% 27.7% 27.0% 29.3% 31.4% 32.5%
EBITDA margin 17.4% −4.2% −10.7% −2.7% −2.4% 7.0% 15.0% 13.1% 20.0% 21.9% 13.7% 13.9% 14.4% 15.5% 17.9% 18.5% 18.7%
Operating margin 14.5% −7.9% −15.5% −7.5% −6.7% 4.0% 12.5% 10.6% 18.4% 20.3% 11.9% 12.2% 12.5% 13.3% 16.1% 16.8% 16.8%
Net margin 11.0% −5.1% −14.6% −4.5% −2.7% 4.1% 23.2% 7.2% 15.3% 17.5% 16.2% 10.9% 15.3% 4.0% 13.5% 17.6% 15.1%
Free-cash-flow margin 10.9% −1.7% −11.1% −3.5% −7.6% 0.8% 12.0% 9.7% 7.1% 12.7% −10.1% −5.9% — — −4.4% 8.7% 13.4%
Cash flow
Cash from operations 3 0 −1 −0 −1 0 3 3 3 5 −2 −1 5 6 −2 7 11
Capital spending 0 0 0 0 0 0 1 1 1 1 2 2 — — 1 0 1
Free cash flow 3 −0 −1 −0 −1 0 3 2 2 4 −4 −2 — — −3 7 11
Stock-based pay 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1
Free cash flow after stock pay 3 −0 −1 −0 −1 0 3 2 2 4 −5 −4 — — −3 6 10
Balance sheet
Cash 5 4 2 3 1 2 4 5 8 6 4 1 3 3 0 8 12
Total debt 1 0 0 0 0 0 0 0 5 5 14 17 17 16 22 22 16
Net debt (negative = net cash) −3 −4 −1 −3 −1 −2 −4 −5 −3 −2 10 16 14 14 21 14 5
Diluted shares 3m 3m 3m 3m 4m 4m 4m 4m 4m 4m 4m 4m 4m 4m 3m 3m 3m
Returned to shareholders
Buybacks — 0 — — 0 0 0 0 4 3 6 2 2 4 4 3 —
Total returned — 0 — — 0 0 0 0 4 3 6 2 2 4 4 3 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 7 checks passed · September 30, 2026
What it owns · $77m
Short-term assets $54mLonger-term assets $23m
What it owes, and who funded it · $77m
Short-term liabilities $13mLonger-term liabilities $14mShareholders' equity $49m
  • Short-term assets cover short-term liabilities $54m of assets due within a year against $13m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $54m short-term assets against $14m of longer-dated liabilities.
  • More cash than debt $12m of cash against $12m of debt.
  • Debt below 40% of shareholders' equity Debt is 25% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 47% to 25% over five years.
  • A year's operating cash flow covers at least 20% of debt $11m of operating cash flow against $12m of debt.
  • Operating profit covers interest at least five times over Operating income of $13m against $872,000 of interest.

From PRO DEX Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$10.4M
Diluted share count
−1.8%
year over year
R&D spending
4.8%
of revenue
Sales & admin spending
10.9%
of revenue
Days sales outstanding
80 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated PDEX TELA SGHT RCEL ELMD LUNG Median
Revenue, last 12 months $80m $80m $83m $76m $74m $87m $99m
Revenue growth, last 12 months 13.3% 6.1% 9.3% 1.0% 15.3% −3.4% 9.2%
Revenue growth, 3-year average 19.2% 17.6% 0.8% 22.8% 15.4% 13.0% 13.5%
Revenue growth, latest quarter 11.0% −4.5% 19.5% 17.8% 11.6% −4.6% 10.2%
Gross margin 32.5% 67.8% 88.0% 81.6% 78.5% 77.1% 61.2%
Operating margin 16.8% −42.6% −33.4% −46.6% 18.8% −53.0% −8.5%
Operating margin, 3-year average 15.6% −50.7% −54.2% −69.8% 15.3% −64.4% −17.9%
Net margin 15.1% −51.5% −35.7% −57.0% 15.3% −55.0% −12.0%
Cash from operations / revenue 14.4% −39.0% −27.9% −32.0% 13.1% −34.9% −1.9%
Free-cash-flow margin 13.4% −39.6% −28.0% −32.5% 11.3% −35.1% −3.9%
Free-cash-flow margin, 3-year average 2.2% −51.2% −34.5% −65.3% 14.8% −39.2% −7.0%
Stock pay / revenue 0.8% 4.0% 12.9% 9.6% 3.7% 19.7% 6.1%
Change in share count −1.8% 14.4% 4.7% 14.7% −2.5% 4.7% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 13.3% 9.1% 53 of 129
Change in growth rate Growth -3.1pp -0.6pp 94 of 129
Gross margin Profitability 32.5% 61.9% 106 of 123
Operating margin Profitability 16.8% -8.3% 18 of 132
Net margin Profitability 15.1% -12.0% 17 of 133
Free-cash-flow margin Cash generation 13.4% -3.4% 24 of 128
Stock pay as % of revenue Cash generation 0.8% 6.1% 4 of 123
Long-term debt as % of assets Balance sheet 16.0% 24.2% 34 of 87
Change in share count Balance sheet -1.8% 3.3% 18 of 115
Days sales outstanding Balance sheet 80 days 57 days 95 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$43M
Institutions reporting
67
Shares held vs prior quarter
▼ 1.8%
Positions opened / closed
16 / 7

Top buyers and sellers, Q2 2026: 39 institutions bought and 26 sold ; the biggest buyer was Pekin Hardy Strauss, Inc (+17K shares) and the biggest seller Northern Trust Corp (−31K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $9M 153K 20.9% ▲ 0.4%
Vanguard Capital Management LLC $4.8M 82K 11.2% ▼ 26.1%
Dimensional Fund Advisors LP $3.3M 57K 7.8% ▲ 0.2%
Punch & Associates Investment Management, Inc. $3.1M 53K 7.2% ▼ 14.6%
Geode Capital Management, LLC $2.9M 50K 6.8% ▲ 2.7%
Jpmorgan Chase & Co $1.9M 32K 4.4% ▲ 0.8%
State Street Corp $1.8M 31K 4.3% ▼ 5.4%
Goldman Sachs Group Inc $1.1M 19K 2.5% ▲ 84.5%
Pekin Hardy Strauss, Inc. $966,075 17K 2.2% New
BNP Paribas Financial Markets $933,580 16K 2.2% ▲ 20.5%
Northern Trust Corp $914,258 16K 2.1% ▼ 66.6%
Vanguard Portfolio Management LLC $839,139 14K 2.0% ▲ 15.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not PRO DEX Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2M 20 trades by 3 insiders · 91% under pre-set plans
Net ▼ $2M net selling
Insider Date Trade Shares Price Value
Van Kirk Richard Lee Jr Chief Executive Officer September 11, 2026 Sell pre-set plan 290 $58.94 $17,093
Van Kirk Richard Lee Jr Chief Executive Officer September 11, 2026 Sell pre-set plan 475 $59.62 $28,320
Charlton Alisha Chief Financial Officer September 9, 2026 Sell 1,500 $61.05 $91,575
Charlton Alisha Chief Financial Officer September 9, 2026 Sell 800 $61.76 $49,408
Van Kirk Richard Lee Jr Chief Executive Officer September 9, 2026 Sell pre-set plan 935 $62.93 $58,840
Van Kirk Richard Lee Jr Chief Executive Officer September 9, 2026 Sell pre-set plan 806 $58.66 $47,280
Van Kirk Richard Lee Jr Chief Executive Officer September 9, 2026 Sell pre-set plan 300 $64.70 $19,410
Van Kirk Richard Lee Jr Chief Executive Officer September 9, 2026 Sell pre-set plan 2,144 $63.85 $136,894
Van Kirk Richard Lee Jr Chief Executive Officer September 9, 2026 Sell pre-set plan 4,768 $59.45 $283,458
Van Kirk Richard Lee Jr Chief Executive Officer September 9, 2026 Sell pre-set plan 1,157 $61.88 $71,595
Van Kirk Richard Lee Jr Chief Executive Officer September 9, 2026 Sell pre-set plan 4,274 $60.72 $259,517
Van Kirk Richard Lee Jr Chief Executive Officer September 9, 2026 Sell pre-set plan 2,691 $59.84 $161,029

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 28, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • September 3, 2026
  • April 30, 2026
  • January 29, 2026
  • October 30, 2025
  • September 4, 2025

Recent SEC filings

Data status

When each part of this page on PRO DEX Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

PRO DEX Inc in brief

What does PRO DEX Inc do?
PRO DEX Inc is a US-listed company in the health care equipment industry. Its financial year ends in June.
What is PRO DEX Inc's stock ticker?
PRO DEX Inc trades under the ticker PDEX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is PRO DEX Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, PRO DEX Inc reported revenue of $79.6M, 13.3% higher than a year earlier, according to its SEC filings.
What is PRO DEX Inc's free cash flow?
PRO DEX Inc's free-cash-flow margin is 13.4% of revenue over the trailing twelve months, ranking 24 of the 128 health care equipment companies we cover.
Who are PRO DEX Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and Dimensional Fund Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is PRO DEX Inc's market cap?
On November 2, 2026, PRO DEX Inc's market capitalisation was about $191M, with a price-to-earnings ratio of 15.9 and net debt of $4.7M. Market figures come from third-party market data and may be delayed.
How much debt does PRO DEX Inc have?
PRO DEX Inc's debt-to-equity ratio is 24.9%, from its latest balance sheet (47.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are PRO DEX Inc's competitors?
In our Health Care Equipment peer group, the companies closest to PRO DEX Inc are Tela Bio, Inc., Sight Sciences, Inc., Avita Medical, Inc., Electromed, Inc. and Pulmonx Corp. The side-by-side comparison below sets their revenue, margins and growth against PRO DEX Inc's.
Are insiders buying or selling PRO DEX Inc stock?
Over the last 12 months, PRO DEX Inc's directors and officers reported 0 open-market purchases and 20 sales on Form 4. The insider trading page charts every trade.
When is PRO DEX Inc's next earnings date?
Around January 28, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — PRO DEX Inc announces its own schedule.